711 related articles for article (PubMed ID: 9560052)
1. Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors.
Bokemeyer C
Oncology; 1998; 55(3):177-88. PubMed ID: 9560052
[TBL] [Abstract][Full Text] [Related]
2. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ
Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
[TBL] [Abstract][Full Text] [Related]
3. Future prospects in the chemotherapy of metastatic nonseminomatous testicular germ-cell cancer.
Hartmann JT; Kuczyk MA; Kollmannsberger C; Kanz L; Bokemeyer C
World J Urol; 1999 Oct; 17(5):324-33. PubMed ID: 10552153
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors.
Bokemeyer C; Köhrmann O; Tischler J; Weissbach L; Räth U; Haupt A; Schöffski P; Harstrick A; Schmoll HJ
Ann Oncol; 1996 Dec; 7(10):1015-21. PubMed ID: 9037359
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and treatment of patients with testicular germ cell cancer.
Hartmann JT; Kanz L; Bokemeyer C
Drugs; 1999 Aug; 58(2):257-81. PubMed ID: 10473019
[TBL] [Abstract][Full Text] [Related]
6. The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors.
Bokemeyer C; Hartmann JT; Kuczyk MA; Truss MC; Beyer J; Jonas U; Kanz L
World J Urol; 1996; 14(6):354-9. PubMed ID: 8986035
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
8. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
9. High-dose chemotherapy in germ-cell tumors.
Droz JP; Culine S; Biron P; Kramar A
Ann Oncol; 1996 Dec; 7(10):997-1003. PubMed ID: 9037356
[TBL] [Abstract][Full Text] [Related]
10. [High dose chemotherapy with autologous stem cell support in the treatment of germ cell tumors: experience of the centre Léon-Bérard between 1982 and 1996].
Fléchon A; Biron P; Philip I; Blay JY; Droz JP
Bull Cancer; 1999 Apr; 86(4):391-9. PubMed ID: 10341344
[TBL] [Abstract][Full Text] [Related]
11. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
[TBL] [Abstract][Full Text] [Related]
12. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
Margolin K; Doroshow JH; Ahn C; Hamasaki V; Leong L; Morgan R; Raschko J; Shibata S; Somlo G; Tetef M
J Clin Oncol; 1996 Oct; 14(10):2631-7. PubMed ID: 8874321
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer.
Motzer RJ; Sheinfeld J; Mazumdar M; Bains M; Mariani T; Bacik J; Bajorin D; Bosl GJ
J Clin Oncol; 2000 Jun; 18(12):2413-8. PubMed ID: 10856101
[TBL] [Abstract][Full Text] [Related]
14. Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German Testicular Cancer Study Group (GTCSG).
Bokemeyer C; Kollmannsberger C; Harstrick A; Beyer J; Gerl A; Casper J; Metzner B; Hartmann JT; Schmoll HJ; Kanz L
Int J Cancer; 1999 Dec; 83(6):848-51. PubMed ID: 10597209
[TBL] [Abstract][Full Text] [Related]
15. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
Culine S; Theodore C; Terrier-Lacombe MJ; Droz JP
J Urol; 1997 Mar; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
[TBL] [Abstract][Full Text] [Related]
16. [Late toxicity after chemotherapy of malignant testicular tumors].
Jakob A; Kollmannsberger C; Kanz L; Bokemeyer C
Urologe A; 1998 Nov; 37(6):635-47. PubMed ID: 9887493
[TBL] [Abstract][Full Text] [Related]
17. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.
Kondagunta GV; Bacik J; Donadio A; Bajorin D; Marion S; Sheinfeld J; Bosl GJ; Motzer RJ
J Clin Oncol; 2005 Sep; 23(27):6549-55. PubMed ID: 16170162
[TBL] [Abstract][Full Text] [Related]
18. Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients.
Soulié P; Garrino C; Bensmaïne MA; Bekradda M; Brain E; Di Palma M; Goupil A; Misset JL; Cvitkovic E
J Cancer Res Clin Oncol; 1999 Dec; 125(12):707-11. PubMed ID: 10592105
[TBL] [Abstract][Full Text] [Related]
19. Treatment of testicular cancer: a new and improved model.
Einhorn LH
J Clin Oncol; 1990 Nov; 8(11):1777-81. PubMed ID: 1700077
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy in patients with metastatic or relapsed germ-cell tumours.
Rick O; Siegert W; Beyer J
Cancer Treat Rev; 2001 Oct; 27(5):283-8. PubMed ID: 11871864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]